Subglobin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Subglobin

Property Description
Active ingredient Human Normal Immunoglobulin
Form Solution for injection (SCIG)
Pharmacological class Immune Globulins
Common use Replacement therapy (immune support)
Origin Human plasma-derived

Subglobin: Definition and Pharmacological Class

Subglobin is a therapeutic agent classified as an Immune globulin (Human), which belongs to the medical class of immunizing agents and blood factors. Its active component is Human Normal Immunoglobulin, a highly purified preparation derived from the pooled plasma of thousands of healthy human donors. Considered a biological agent, Subglobin functions as a replacement therapy product, supplying critical antibodies that are missing or insufficient in the patient's immune system. Human Normal Immunoglobulin contains a broad spectrum of Immunoglobulin G (IgG) antibodies, offering general protective capabilities. This establishes the medicine as a pooled defense mechanism designed for comprehensive immune support, a function supported by decades of clinical experience.

Composition, Origin, and Form of Subglobin

The therapeutic action of Subglobin relies on its human plasma-derived origin, yielding a product composed of at least 95% intact, functional Immunoglobulin G (IgG), which includes all four main IgG subclasses. As a differentiating feature, Subglobin is formulated specifically as an SCIG (Subcutaneous Solution for injection). This preparation contrasts with intravenous immunoglobulin (IVIG) products in its physical properties and intended route. The formulation is an aqueous solution containing stabilizing excipients, meeting the rigorous quality criteria set by regulatory bodies.

General Purpose of Immune Globulin Therapy

The core purpose of this therapy is to provide passive immunity, thereby serving to strengthen the body's protective capabilities against infectious pathogens. By directly supplying a comprehensive and functional antibody repertoire in the form of IgG, Subglobin helps to reduce a patient's overall susceptibility to a wide variety of viral and bacterial infections. Human Immune Globulin is clinically recognized to improve the body’s resistance to disease by providing necessary antibodies. This replacement function is essential for individuals with certain immune deficits, compensating for their inability to produce sufficient or effective IgG antibodies naturally.

Regulatory References

  1. Intravenous Immunoglobulin (IVIG)
  2. EMA guideline on core SmPC for human normal immunoglobulin
  3. EMA Guideline on core SmPC for SCIG/IMIg
  4. Immune Globulin Subcutaneous (Human) Drug Information

What side effects are possible with Subglobin?

Possible Side Effects and Safety Information

The safety profile of Subglobin (Human Normal Immunoglobulin) is defined by classifications established in official government regulatory documents, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC). Adverse reactions are formally grouped by frequency and the body's systems they affect.

Reactions are often more frequently observed at the start of treatment or during dose escalation.


Adverse Reactions by Classification

Classification System-Organ Class Examples
Common (ge 1/100 to < 1/10) General Disorders and Administration Site Conditions (local pain, swelling, warmth, fever); Nervous System Disorders (headache); Gastrointestinal Disorders (nausea, vomiting); Musculoskeletal Disorders (myalgia, arthralgia).
Uncommon (ge 1/1,000 to < 1/100) Dizziness, rash.
Rare Anaphylaxis, Thromboembolic Events, Acute Kidney Injury, Haemolysis.

Serious Adverse Reactions and Safety Cautions

The label documents the potential for rare, serious adverse events. These include Anaphylactic and Severe Hypersensitivity Reactions, particularly noted for patients with an anti-IgA deficiency. Warnings also cite the risk for Thromboembolic Events (blood clots) and Acute Kidney Injury (AKI), which are higher in certain patient subgroups.

Regulatory cautions specify that patients with pre-existing renal impairment or cardiovascular risk factors are noted to be at increased risk for AKI and thromboembolic events, respectively. These safety domains provide the necessary framework for understanding the medicine's official, label-derived risk profile.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Subglobin (Human Normal Immunoglobulin SCIG) addresses overdose primarily as a consequence of administration errors, focusing on volume and infusion rate, rather than intrinsic product toxicity.

Documented Manifestations and Actions

Overdose is generally associated with an excessive volume or too high an infusion rate, which may lead to clinical signs of hypervolaemia (fluid overload) and hyperviscosity (increased blood thickness). In the event of suspected overdose, the infusion must be halted immediately.

Management is restricted to symptomatic and supportive treatment, as no specific pharmacological antidote is documented in the official labeling.

When Urgent Medical Help is Required

Immediate medical attention is mandated for severe, sudden, or life-threatening reactions. This includes symptoms associated with shock, anaphylaxis, or the clinical manifestation of a thromboembolic event (blood clot). These situations require contacting emergency medical services without delay.

Patients who are elderly or have pre-existing conditions such as renal impairment are officially noted to be at a heightened risk for severe outcomes when exposed to high doses or rapid administration, necessitating close clinical observation.

Therapeutic Uses of Subglobin

What Subglobin Treats: Main Uses and Benefits

Subglobin is a supportive treatment applied across domains where additional symptomatic support is needed for patients experiencing complex or recurrent health challenges. The medicine plays a role in managing conditions characterized by systemic or localized discomfort and helps address symptoms that create noticeable physiological strain.

Human Normal Immunoglobulin is commonly used across conditions presenting with acute episodes. The primary uses include management of symptoms related to primary and secondary immunodeficiency syndromes, as well as conditions like immune thrombocytopenia (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP).

“Subglobin provides support that helps ease the overall burden of symptoms and helps patients cope more steadily with difficult symptom fluctuations.”


Managing Episodic Symptom Fluctuation

This domain covers conditions involving episodic or fluctuating manifestations where symptoms associated with acute or episodic changes create instability. Subglobin contributes to easing the overall symptom load and is relevant in contexts involving heightened systemic burden during these challenging periods.

Relief from Acute Symptom Clusters

Subglobin is applied in clinical settings marked by increased discomfort where groups of symptoms appear suddenly. It helps address symptom clusters that may become intense or disruptive, which supports patients during episodes of heightened discomfort and provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Relevant for Symptoms that interfere with daily functioning


Support for Functional Strain

This use is relevant when symptoms create noticeable physiological strain or lead to temporary functional instability. The medicine helps improve day-to-day comfort during symptomatic periods, providing supportive relief when symptoms lead to temporary functional strain or discomfort.

Regulatory References

  1. European Medicines Agency EPAR for Privigen, which contains Human Normal Immunoglobulin

Eligibility and Restrictions for Use

Who Can and Cannot Use Subglobin?

The official eligibility for Subglobin (Human Normal Immunoglobulin SCIG) is determined by regulatory-mandated contraindications and cautionary use requirements. Eligibility is established for adults and children with Primary Immunodeficiency (PI) syndromes and certain secondary immunodeficiencies.


Absolute Non-Eligibility (Contraindications)

Subglobin must not be used by individuals with a history of anaphylactic or severe systemic hypersensitivity reactions to Human Immunoglobulin. It is also contraindicated in IgA-deficient patients who have known antibodies against IgA, as this condition significantly increases the risk of severe allergic reactions.


Conditional Use and Restrictions

Certain populations require caution and monitoring:

Population/Condition Restriction Status
Pediatric Patients Not established or approved in children younger than 2 years for some PI indications.
Geriatric Patients Use requires caution due to increased susceptibility to risks like acute renal failure.
Renal Impairment Patients with pre-existing kidney issues require close monitoring.
Pregnancy/Lactation Use only if benefit clearly outweighs potential risk; not absolutely contraindicated.

These rules ensure that the medicine is used only when the patient's medical status aligns with the officially documented safety profile.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Subglobin (Human Normal Immunoglobulin) is defined by its function as an antibody replacement product, resulting in pharmacodynamic restrictions rather than metabolic drug-drug interactions.

Documented Pharmacodynamic Interference

The principal interaction documented in regulatory sources involves Live Attenuated Virus Vaccines, including those for Measles, Mumps, Rubella, and Varicella. The passive transfer of high levels of Immunoglobulin G (IgG) antibodies may temporarily impair the efficacy of these vaccines, as the administered antibodies can interfere with the development of the recipient's own active immune response.

This necessitates a timing separation requirement: official prescribing information specifies that administration of these vaccines must be postponed for a mandatory period, typically a minimum of three months following the administration of Subglobin. The exact required separation interval can extend further depending on the specific vaccine and the dose of immunoglobulin received.

Other Interaction-Related Restrictions

Interacting Product Category Type of Restriction Regulatory Basis
Loop Diuretics Use is restricted or cautioned against in patients with specific underlying risk factors, such as pre-existing renal impairment or thrombosis risk. Cautionary Statement (Conditional Restriction)

Subglobin is a biological agent and is not documented to interact with common drug-metabolizing enzymes (such as Cytochrome P450 enzymes) or drug transporters. No specific interactions with food, alcohol, or herbal products are documented in official regulatory labels.

Mechanism of Action

The core mechanism of Subglobin (Human Normal Immunoglobulin) is the passive replenishment of a deficient immune component, ensuring continuous availability of functional antibodies for systemic defense. This action is rooted in two primary, interwoven functions of the supplied Immunoglobulin G ( IgG).

Direct Molecular Binding and Neutralization

Subglobin's mechanism begins at the molecular level with the variable ( F(ab)'2) regions of its polyclonal IgG population. These regions immediately bind to the surface antigens of invading pathogens and microbial toxins, a process termed neutralization. This molecular binding directly blocks the pathogen's functional sites and prevents its interaction with host cell receptors, establishing immediate, passive systemic defense capacity.

Accelerated Pathogen Clearance and Opsonization

Following neutralization, the constant ( Fc) region of the bound IgG acts as a specialized tag. This tag engages Fc receptors ( Fcgamma Rs) on phagocytic immune cells, accelerating the removal process through opsonization and destruction of the marked pathogens. The IgG also activates the classical complement cascade to further support microbial clearance, leading to functional restoration of the body's humoral defense capacity.

Dosage and Administration Information

Administration Overview

Subglobin is designed for subcutaneous infusion, a process where the medication is delivered into the fatty tissue layer directly beneath the skin. This method allows for a steady absorption of the immunoglobulin into the systemic circulation.

Preparation for Use

Before beginning the infusion process, the solution should be inspected visually. The liquid should appear clear and colorless or pale yellow. If the solution is cloudy, contains particulate matter, or has changed color, it should not be used.

To ensure comfort during the procedure, it is common practice to allow the medication to reach room temperature naturally. External heat sources should not be used for this purpose.

Site Selection

Typical areas for subcutaneous infusion include the abdomen, thighs, upper arms, or the lateral hip area. It is important to rotate infusion sites regularly to maintain skin integrity and promote optimal absorption. Avoid areas where the skin is bruised, red, scarred, or hardened.

The Infusion Process

The medication is administered using an infusion pump system specifically designed for subcutaneous delivery. The process involves several key steps:

  • Site Cleaning: The chosen skin area is cleaned using an antiseptic solution.
  • Needle Insertion: A small needle or infusion set is inserted at a 90-degree angle (or as specified by the infusion set design) into the subcutaneous tissue.
  • Securing the Set: The needle is typically held in place with a transparent adhesive dressing to ensure it remains stable throughout the duration of the infusion.
  • Initiating Flow: The infusion pump is started to deliver the medication at the required rate.

Multiple Infusion Sites

Depending on the total volume to be delivered, more than one infusion site may be used simultaneously. If multiple sites are utilized, they should be spaced sufficiently apart—generally several inches—to ensure patient comfort and effective absorption.

Completion

Once the infusion is complete, the needle is removed, and a small bandage may be applied to the site. It is normal to observe slight swelling or redness at the injection site immediately following the procedure; this usually dissipates within 24 hours.

Recent Clinical Evidence

Research Evidence for Replacement Therapy in Primary Immunodeficiency (PID)

Research for Subglobin has explored its role as a replacement therapy for individuals with antibody deficiencies who require continuous immune support. Studies, including Randomized Controlled Trials, have examined patterns in the frequency of serious bacterial infections and antibiotic usage. These trials reported measurements of maintained Immunoglobulin G (IgG) Trough Levels. Long-term follow-up primarily relies on observational data, and evidence is limited by the small number of placebo-controlled studies.


Research Evidence for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

The evidence base for CIDP includes Randomized Controlled Trials that have explored the effects of Subglobin by measuring changes in functional status and muscle strength. Research reported that functional scores and overall disability measures were maintained when patients transitioned from intravenous products. A significant portion of this evidence focused on maintaining stability in previously responsive patients, and limited information is available for less common CIDP subtypes.


Research Evidence for Secondary Immunodeficiency (SID)

Evidence in this domain is primarily composed of Systematic Reviews and Real-World Evidence, focusing on infection frequency, patterns of antibiotic usage, and hospitalizations in adults with acquired antibody deficiencies. Research contributes to understanding the patterns of IgG level maintenance. The volume of Subglobin-specific data in SID is limited compared to Primary Immunodeficiency, and results apply only to the studied populations due to inherent patient heterogeneity.


Long-term Studies and Durability of Follow-up

Research has explored the durability of Subglobin's effects beyond the initial short-term clinical trials. This area primarily relies on long-term extension studies and observational registries which monitor outcomes over several years. Findings describe group patterns, not personal outcomes, and limited information is available for long-term outcomes derived from highly controlled research settings.


Research Gaps and Areas of Uncertainty

The research has established evidence in key areas, but is ongoing and more information is needed. One key gap is the limited information for long-term outcomes derived from large, head-to-head controlled trials. Additionally, comparative evidence is lacking for some distinct subgroups within the studied conditions, and findings for special populations like older adults are still emerging.

Key Studies & References Immunoglobulin replacement therapy in secondary immunodeficiency: Current evidence and practical considerations (Systematic Review on SID evidence)

Frequently Asked Questions (FAQ)

Common questions about Subglobin (FAQ)


Q: How quickly does Subglobin start to work?

A: The medicine's action is described as the passive transfer of functional antibodies, which provides immediate replenishment of the immune system’s defense capacity upon administration. However, the exact timeframe for achieving therapeutic benefit can vary among individuals.


Q: How long do the effects of Subglobin last after taking it?

A: The duration of the medicine’s action is related to the natural clearance of the functional antibodies, known as Immunoglobulin G (IgG). Official information indicates that the elimination half-life of IgG is variable among patients, which is why consistent administration, often weekly, is necessary to maintain the required therapeutic levels.


Q: Is Subglobin the same as other 'globin' drugs I've heard of?

A: Subglobin is specifically classified as a Subcutaneous Immune Globulin (SCIG) product. This formulation is distinct from Intravenous Immune Globulin (IVIG) products primarily in its chemical formulation and the approved method of administration.


Q: Is it okay to drink alcohol while using Subglobin?

A: According to official regulatory documents, no specific interactions are documented between Subglobin and alcohol. If there are concerns about alcohol use, patients are advised to discuss this with their healthcare provider.


Q: What is Subglobin known to interact with common pain relievers like ibuprofen?

A: Regulatory documents indicate that this medicine is a biological agent and does not typically interfere with common drug-metabolizing enzymes. This information indicates that systemic interactions with most common non-prescription pain relievers are unlikely.


Q: What does the official product information say about Subglobin and pregnancy?

A: Official product information addresses the use of Subglobin during pregnancy and breastfeeding. It advises that the medicine should be used only when the prescribing healthcare professional determines that the anticipated benefits outweigh the potential risks.


Q: Can Subglobin be used by children?

A: Subglobin is approved for use in pediatric patients for Primary Immunodeficiency (PI). However, official regulatory information specifies that safety and efficacy have not been established in children younger than 2 years old for all approved indications.


Q: Is Subglobin safe for use by older adults?

A: Official information states that use in geriatric patients requires caution and close monitoring. This is due to the official caution that this population may have an increased risk for conditions like acute renal failure or thrombosis (blood clots).


Q: How is the dose of Subglobin typically decided by a healthcare provider?

A: The dosage is determined individually for each patient. The initial weekly dose is calculated based on the patient's previous or calculated intravenous immunoglobulin dose to maintain an appropriate therapeutic concentration.


Q: Is Subglobin a type of antibiotic or steroid?

A: Subglobin is classified as an Immune Globulin, an antibody replacement product. It is not an antibiotic, which kills bacteria, nor is it chemically classified as a steroid.


Q: Does Subglobin cause weight gain or loss?

A: Official safety classification tables listing common and frequent side effects do not list changes in body weight as an expected reaction.


Q: Is Subglobin a treatment that cures a condition, or does it manage symptoms?

A: Subglobin is officially described as a 'replacement therapy' for immune deficiencies. Its function is to manage and maintain protective immune function by supplying necessary antibodies, rather than providing a cure for the underlying condition.


Q: Do cold or allergy medicines interact with Subglobin?

A: Regulatory documents suggest that Subglobin is unlikely to have systemic interactions with most common over-the-counter cold or allergy medicines. This is because the medicine does not interfere with the common drug-metabolizing enzymes.


Q: Is Subglobin known to be a habit-forming medicine?

A: Official prescribing information does not list Subglobin as a controlled substance. Furthermore, no warnings regarding abuse potential or habit formation are documented.


Q: Is there a minimum age requirement for using Subglobin according to official sources?

A: Official regulatory documents indicate that safety and efficacy have not been established for patients younger than 2 years old for certain approved indications.


Q: Does Subglobin affect blood pressure?

A: While not a common side effect, official documents list hypertension (high blood pressure) as an uncommon adverse reaction. There is also potential for rare, serious thromboembolic events.


Q: What happens if a dose of Subglobin is missed?

A: The medicine is intended to maintain consistent protective antibody levels. Missing a dose may lead to a reduction in protective antibody levels, which may in turn increase the susceptibility to infection.


Q: Can Subglobin be crushed or split?

A: The medicine is a sterile solution intended only for subcutaneous infusion (injection). It is not formulated or approved for oral administration, meaning it cannot be crushed, split, or ingested as a pill.


Q: Does Subglobin require a special diet while being used?

A: Official regulatory documents state that there are no specific interactions documented between the medicine and food. Therefore, a special diet is not typically required while using Subglobin.


Q: Is it normal to feel tired after starting Subglobin?

A: Fatigue or tiredness is not explicitly named on the official list of common side effects. However, related general adverse events such as headache and fever are listed as common side effects.


Q: How is Subglobin different from a placebo in clinical trials?

A: In clinical trials, Subglobin provides functioning antibodies for immune support, whereas a placebo is an inactive substance. The trials are designed to assess the clinical benefit provided by the replacement therapy over the inactive substance.


Q: Why is Subglobin sometimes given by injection instead of a pill?

A: Subglobin is a complex human protein called Immunoglobulin G (IgG). If it were taken as a pill, it would be broken down and destroyed by the digestive system before it could enter the bloodstream and work. Therefore, it must be given by infusion (injection).


Q: Does Subglobin affect sleep patterns?

A: Common side effects affecting the nervous system, such as dizziness and headache, are noted in official documents. However, specific effects on sleep patterns are not commonly or explicitly listed.


Q: What does the research say about Subglobin's use in different ethnic groups?

A: Official research summaries often contain demographic information about the clinical trial participants. However, the safety and efficacy findings are typically reported across the overall studied population rather than detailing specific differences across ethnic groups.


Q: Do any official sources suggest monitoring lab tests while using Subglobin?

A: Official documents contain recommendations for monitoring blood work. This may include checking kidney function tests (serum creatinine) and potentially monitoring Immunoglobulin G (IgG) trough levels, depending on the condition being treated.


Q: Where can I find the official regulatory documents for Subglobin?

A: Official prescribing information is made available by regulatory bodies. This information can typically be found on government websites, such as the FDA (DailyMed) or the European Medicines Agency (EMA) Summary of Product Characteristics.

How should Subglobin be stored and disposed of?

Official Storage and Disposal Requirements

Subglobin must be stored and handled strictly according to the following official regulatory requirements to maintain its stability.

Requirement Type Official Labeled Condition
Temperature Store refrigerated, typically between 2 C and 8 C (36 F to 46 F). Do not freeze the product.
Protection Keep in the original outer carton to protect from light.
Safety Must be stored out of the sight and reach of children.
Inspection Visually inspect before use; discard if the solution is cloudy, discolored, or contains particulates.
Disposal Vials are for single-use only; any unused portion must be discarded. Used needles and syringes must be placed in an FDA-cleared sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Subglobin found in:

A-Z Index: